دورية أكاديمية

Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial

التفاصيل البيبلوغرافية
العنوان: Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial
المؤلفون: Pradeesh Sivapalan, Niklas R. Jørgensen, Alexander G. Mathioudakis, Josefin Eklöf, Therese Lapperre, Charlotte Suppli Ulrik, Helle F. Andreassen, Karin Armbruster, Praleene Sivapalan, Julie Janner, Nina Godtfredsen, Ulla M. Weinreich, Thyge L. Nielsen, Niels Seersholm, Torgny Wilcke, Philipp Schuetz, Tobias W. Klausen, Kristoffer Marså, Jørgen Vestbo, Jens-Ulrik Jensen
المصدر: Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
بيانات النشر: BMC, 2020.
سنة النشر: 2020
المجموعة: LCC:Diseases of the respiratory system
مصطلحات موضوعية: Adverse effects, Bone remodelling, Bone turnover markers, Chronic obstructive pulmonary disease, Corticosteroids, Diseases of the respiratory system, RC705-779
الوصف: Abstract Background Long-term treatment with corticosteroids causes loss of bone density, but the effects of using short-term high-dose systemic-corticosteroid therapy to treat acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to determine whether high-dose corticosteroid therapy affected bone turnover markers (BTMs) to a greater extent compared to low-dose corticosteroid therapy. Methods The CORTICO-COP trial (NCT02857842) showed that an eosinophil-guided corticosteroid intervention led to approximately 60% lower accumulated corticosteroid dose for hospitalized patients with AECOPD (low-dose group) compared with 5-day standard corticosteroid treatment (high-dose group). We compared the levels of BTMs C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) in 318 participants during AECOPD and at 1- and 3-month follow-up visits. Results CTX decreased and P1NP increased significantly over time in both treatment groups. There were no significant differences between the groups at 1- or 3-months follow-up for P1NP. A significant drop in CTX was seen at 3 months (down Δ24% from the baseline, p = 0.017) for the high dose group. Conclusion Short-term, high-dose systemic corticosteroid treatment caused a rapid suppression of biomarkers of bone resorption. Corticosteroids did not suppress biomarkers of bone formation, regardless of patients receiving low or high doses of corticosteroids. This therapy was, therefore, harmless in terms of bone safety, in our prospective series of COPD patients. Trial registration ClinicalTrials.gov Identifier: NCT02857842 . Submitted August 2nd, 2016.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1465-993X
20614454
العلاقة: http://link.springer.com/article/10.1186/s12931-020-01531-9Test; https://doaj.org/toc/1465-993XTest
DOI: 10.1186/s12931-020-01531-9
الوصول الحر: https://doaj.org/article/bc1187ba20614454bf48856290fbb5a8Test
رقم الانضمام: edsdoj.bc1187ba20614454bf48856290fbb5a8
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:1465993X
20614454
DOI:10.1186/s12931-020-01531-9